The benefit of using Ga-68-PSMA PET for patients with biochemical recurrence after radical prostatectomy is high [1, 2], and a delayed-time-point (DTP) acquisition protocol has proved to improve the capacity of Ga-68-PSMA PET to detect prostate cancer metastases [3]. Here, FOLH1 is linked to prostate cancer.